- Home
- BWBBP vs CGEN Comparison
BWBBP vs CGEN Comparison
Compare BWBBP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWBBP
- CGEN
- Stock Information
- Founded
- BWBBP N/A
- CGEN 1993
- Country
- BWBBP United States
- CGEN Israel
- Employees
- BWBBP 290
- CGEN N/A
- Industry
- BWBBP Major Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWBBP Finance
- CGEN Health Care
- Exchange
- BWBBP Nasdaq
- CGEN Nasdaq
- Market Cap
- BWBBP N/A
- CGEN 167.4M
- IPO Year
- BWBBP N/A
- CGEN 2000
- Fundamental
- Price
- BWBBP $18.58
- CGEN $1.76
- Analyst Decision
- BWBBP
- CGEN
- Analyst Count
- BWBBP 0
- CGEN 0
- Target Price
- BWBBP N/A
- CGEN N/A
- AVG Volume (30 Days)
- BWBBP N/A
- CGEN 181.3K
- Earning Date
- BWBBP N/A
- CGEN 08-05-2025
- Dividend Yield
- BWBBP N/A
- CGEN N/A
- EPS Growth
- BWBBP N/A
- CGEN N/A
- EPS
- BWBBP N/A
- CGEN N/A
- Revenue
- BWBBP N/A
- CGEN $27,589,000.00
- Revenue This Year
- BWBBP N/A
- CGEN N/A
- Revenue Next Year
- BWBBP N/A
- CGEN $173.80
- P/E Ratio
- BWBBP N/A
- CGEN N/A
- Revenue Growth
- BWBBP N/A
- CGEN N/A
- 52 Week Low
- BWBBP N/A
- CGEN $1.13
- 52 Week High
- BWBBP N/A
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- BWBBP 49.17
- CGEN 59.85
- Support Level
- BWBBP $18.43
- CGEN $1.62
- Resistance Level
- BWBBP $18.56
- CGEN $1.81
- Average True Range (ATR)
- BWBBP 0.10
- CGEN 0.08
- MACD
- BWBBP 0.01
- CGEN 0.00
- Stochastic Oscillator
- BWBBP 77.39
- CGEN 78.26
About BWBBP Bridgewater Bancshares Inc. Depositary Shares Each Representing a 1/100th Interest in a Share of 5.875% Non-Cumulative Perpetual Preferred Stock Series A
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.